Grepafloxacina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Grepafloxacina" in Italian language version.

refsWebsite

Global rank Italian rank

12nih.gov

4^th place

9^th place

5oxfordjournals.org

1,389^th place

732^nd place

2asm.org

3,555^th place

2,382^nd place

2fda.gov

447^th place

644^th place

2doi.org

2^nd place

7^th place

1jst.go.jp

1,903^rd place

3,782^nd place

1oadoi.org

799^th place

22^nd place

asm.org

aac.asm.org

Neu HC, Fang W, Gu JW, Chin NX, In vitro activity of OPC-17116, in Antimicrob. Agents Chemother., vol. 36, n. 6, giugno 1992, pp. 1310–5, PMC 190337, PMID 1329620. URL consultato il 12 ottobre 2014.
Chodosh S, Lakshminarayan S, Swarz H, Breisch S, Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily, in Antimicrob. Agents Chemother., vol. 42, n. 1, gennaio 1998, pp. 114–20, PMC 105465, PMID 9449270. URL consultato il 12 ottobre 2014.

doi.org

dx.doi.org

Geddes AM., Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety., in Expert Opin Investig Drugs., vol. 8, n. 4, aprile 1999, pp. 487-505, DOI:10.1517/13543784.8.4.487, PMID 15992094. URL consultato il 12 ottobre 2014.
McCormack WM, Martin DH, Hook EW, Jones RB, Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection, in Infect Dis Obstet Gynecol, vol. 6, n. 3, 1998, pp. 109–15, DOI:10.1155/S1064744998000210, PMC 1784789, PMID 9785106. URL consultato il 12 ottobre 2014.

fda.gov

Glaxo Wellcome voluntarily withdraws Raxar (grepafloxacin) - 27/10/1999 (PDF), su fda.gov. URL consultato il 12 ottobre 2014.
Letter - Raxar, su fda.gov, FDA - U.S. Food and Drug Administation. URL consultato il 12 ottobre 2014.

jst.go.jp

joi.jlc.jst.go.jp

Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y, Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells, in Drug Metab. Pharmacokinet., vol. 20, n. 6, dicembre 2005, pp. 491–5, PMID 16415534. URL consultato il 12 ottobre 2014.

nih.gov

ncbi.nlm.nih.gov

Neu HC, Fang W, Gu JW, Chin NX, In vitro activity of OPC-17116, in Antimicrob. Agents Chemother., vol. 36, n. 6, giugno 1992, pp. 1310–5, PMC 190337, PMID 1329620. URL consultato il 12 ottobre 2014.
Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y, Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells, in Drug Metab. Pharmacokinet., vol. 20, n. 6, dicembre 2005, pp. 491–5, PMID 16415534. URL consultato il 12 ottobre 2014.
Sprandel KA, Rodvold KA, Safety and tolerability of fluoroquinolones, in Clin Cornerstone, Suppl 3, 2003, pp. S29–36, PMID 14992418.
Stahlmann R, Lode H, Toxicity of quinolones, in Drugs, 58 Suppl 2, 1999, pp. 37–42, PMID 10553703.
Chodosh S, Lakshminarayan S, Swarz H, Breisch S, Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily, in Antimicrob. Agents Chemother., vol. 42, n. 1, gennaio 1998, pp. 114–20, PMC 105465, PMID 9449270. URL consultato il 12 ottobre 2014.
Langan CE, Cranfield R, Breisch S, Pettit R, Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 63–72, PMID 9484875. URL consultato il 12 ottobre 2014.
Langan CE, Zuck P, Vogel F, McIvor A, Peirzchala W, Smakal M, Staley H, Marr C, Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis, in J. Antimicrob. Chemother., vol. 44, n. 4, ottobre 1999, pp. 515–23, PMID 10588313. URL consultato il 12 ottobre 2014.
O'Doherty B, Dutchman DA, Pettit R, Maroli A, Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 73–81, PMID 9484876. URL consultato il 12 ottobre 2014.
Felmingham D, Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms, in J. Antimicrob. Chemother., vol. 45, marzo 2000, pp. 1–8, PMID 10719006. URL consultato il 12 ottobre 2014.
Geddes AM., Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety., in Expert Opin Investig Drugs., vol. 8, n. 4, aprile 1999, pp. 487-505, DOI:10.1517/13543784.8.4.487, PMID 15992094. URL consultato il 12 ottobre 2014.
Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D, The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 31–4, PMID 9484871. URL consultato il 12 ottobre 2014.
McCormack WM, Martin DH, Hook EW, Jones RB, Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection, in Infect Dis Obstet Gynecol, vol. 6, n. 3, 1998, pp. 109–15, DOI:10.1155/S1064744998000210, PMC 1784789, PMID 9785106. URL consultato il 12 ottobre 2014.

oadoi.org

Geddes AM., Grepafloxacin: an overview of antibacterial activity, pharmacokinetics, clinical efficacy and safety., in Expert Opin Investig Drugs., vol. 8, n. 4, aprile 1999, pp. 487-505, DOI:10.1517/13543784.8.4.487, PMID 15992094. URL consultato il 12 ottobre 2014.

oxfordjournals.org

jac.oxfordjournals.org

Langan CE, Cranfield R, Breisch S, Pettit R, Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 63–72, PMID 9484875. URL consultato il 12 ottobre 2014.
Langan CE, Zuck P, Vogel F, McIvor A, Peirzchala W, Smakal M, Staley H, Marr C, Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis, in J. Antimicrob. Chemother., vol. 44, n. 4, ottobre 1999, pp. 515–23, PMID 10588313. URL consultato il 12 ottobre 2014.
O'Doherty B, Dutchman DA, Pettit R, Maroli A, Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 73–81, PMID 9484876. URL consultato il 12 ottobre 2014.
Felmingham D, Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms, in J. Antimicrob. Chemother., vol. 45, marzo 2000, pp. 1–8, PMID 10719006. URL consultato il 12 ottobre 2014.
Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D, The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp, in J. Antimicrob. Chemother., 40 Suppl A, dicembre 1997, pp. 31–4, PMID 9484871. URL consultato il 12 ottobre 2014.